Lv2
139 积分 2023-05-24 加入
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
30天前
已完结
690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
1个月前
已完结
B7-H3 immunoregulatory roles in cancer
2个月前
已完结
New checkpoints in cancer immunotherapy
2个月前
已完结
CDK inhibitors from past to present: A new wave of cancer therapy
2个月前
已完结
Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis
2个月前
已完结
Cyclin-Dependent Kinase 2 (CDK2) Inhibitors and others novel CDK Inhibitors (CDKi) in Breast Cancer: Clinical Trials, Current Impact, and Future Directions
2个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
2个月前
已完结
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
2个月前
已完结
KLRG1 Cell Depletion As A Novel Therapeutic Strategy In Patients With Mature T-cell lymphoma Subtypes
2个月前
已完结
皖公网安备34019202002308
